The Enterocolitis drugs in development market research report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Enterocolitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Enterocolitis and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Enterocolitis by 17 companies/universities/institutes. The top development phase for Enterocolitis is preclinical with 13 drugs in that stage. The Enterocolitis pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Enterocolitis pipeline products market are: Leadiant Biosciences, Liminal BioSciences and University of Pittsburgh.
The key targets in the Enterocolitis pipeline products market include Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1), Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12), and Toll Like Receptor 4 (hToll or CD284 or TLR4).
The key mechanisms of action in the Enterocolitis pipeline product include Toll Like Receptor 4 (hToll or CD284 or TLR4) Antagonist with one drug in Preclinical. The Enterocolitis pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Enterocolitis pipeline products market including Biologic, and Small Molecule.
Enterocolitis overview
Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding, and sluggishness. Causes of enterocolitis include inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis, and cardiovascular collapse. Treatment includes antibiotics.
For a complete picture of Enterocolitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
